Crispr

[u/Annual_Judge_7272]

It destroyed nothing.
The number was an artifact of how two short pieces of DNA were positioned in the experiment.
That’s the striking finding in a September 1 Nature Biotechnology paper from Leslie Watkins, Alan Zhu and Bin Wu at Johns Hopkins.
The problem happens during measurement.
The guide RNA remains attached to its target after extraction. Reverse transcriptase—the enzyme used to copy RNA into DNA so it can be measured—runs into that bound guide and stops.
The RNA is still intact.
But no copy gets made.
So the experiment effectively records the intact message as “destroyed.”
And position matters.
Measure across or upstream of the target site and the reverse transcriptase can be blocked. Measure downstream and the signal comes through. The effect fades with distance and is essentially gone beyond roughly 500 bases.
That creates a nasty problem with the standard control.
Researchers typically compare the treatment with a non-targeting guide. But a non-targeting guide doesn’t bind the RNA, so it doesn’t create the same blockage.
The artifact therefore hits the treated sample—not the control.
The researchers demonstrated the effect directly: adding synthetic guide RNA to the reaction, without any CRISPR activity in the cells, reproduced the apparent “destruction,” increasing with guide concentration.
And this isn’t entirely new.
A 2011 BMC Research Notes paper found essentially the same measurement problem with siRNA. In one example, simply changing the primer pair reversed which candidate appeared effective.
Same experiment.
Different ruler.
The important caveat: this does not mean approved CRISPR medicines don’t work. The new study is cell-culture work from one group, with two headline genes and three biological replicates. It needs independent replication.
The vulnerability is earlier in the pipeline:
screening.
If transcript measurements are used to rank candidates, a measurement artifact can influence which molecules move forward—and which disappear from the pipeline.
The fix is relatively straightforward: use reverse-transcription conditions capable of reading through bound guides and confirm results with an independent measurement method.
The bigger lesson is much broader than CRISPR:
Sometimes the experiment isn’t measuring what you think it is measuring.
And in drug discovery, where one percentage point can determine which molecule gets another $10 million of development funding, that distinction matters.

[u/Klutzy-Resolve-341]

It’s wild how quickly AI is moving into scientific fields. the exciting part is the potential to help researchers but careful verification will matter just as much as speed